Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
Key Points
Key Points
Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.
Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.
The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.
Treatment
...atment...
...atients who have active malignancy and acute...
...ospitalized patients who have active...
...pharmacologic thromboprophylaxis should not be...
...macologic thromboprophylaxis should n...
...gh-risk outpatients with cancer (K...
...th multiple myeloma receiving thalidomide- or l...
...patients with malignant disease undergoi...
...axis with UFH or LMWH should be comm...
...nical methods may be added to pharmacolo...
...ed regimen of pharmacologic and mechanica...
...thromboprophylaxis for patients undergoing major...
Extended pharmacologic thromboprophylaxis for...
(Updated) Patients who are candidates for exten...
...pdated) Alternatively, patients may be offered pr...
...nitial anticoagulation may involve LMWH, UFH, fo...
...dated) For long-term anticoagulation, LMWH,...
Anticoagulation with LMWH, direct fa...
...opinion in the absence of randomized...
...nsertion of a vena cava filter may be off...
...r patients with primary or metastatic...
...and deep vein thrombosis should be treated in...
Treatment of isolated subsegmental PE or...
...nt use is not recommended to improve s...
...ubstantial variation in risk of VTE betwe...
...ogists and members of the oncology team...
...ng off-label use in guideline recomm...
Table 2. Predictive Model for Chemotherap...